Conditions: Breast Cancer
Keywords: breast cancer adjuvant treatment in post menopausal women letrozole arthralgia-myalgia
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 261
Healthy volunteers: no

Brief summary:
This study will evaluate whether patients who are intolerant and discontinue anastrozole due to grade 2-3 arthralgia-myalgia have a decrease in rheumatological symptoms while taking letrozole

Detailed description:
This is a multi-center prospective non-randomized single arm, open label trial in postmenopausal HR positive early breast cancer patients who experience grade 2-3 arthralgia-myalgia while on anastrozole, resulting in the discontinuation of anastrozole. After a 2-3 week period without any aromatase inhibitor treatment, eligible patients will initiate letrozole treatment at a dose of 2.5mg per day for a duration of 24 weeks. If a patient has breast cancer recurrence or is intolerant to letrozole during the 24 week period, the drug will be discontinued.

Arms:
arm 1: Participants received 2.5 milligram (mg) of Letrozole tablets orally once daily (QD) for a period of 24 weeks.

Interventions: intervention 1: letrozole
Intervention descriptions: intervention 1: 2.5 mg daily by mouth for 6 months

Protocol document: